Core Insights - JiuZhiTang's stock increased by 5.08% to 10.54 CNY per share, with a trading volume of 337 million CNY and a turnover rate of 4.74%, resulting in a total market capitalization of 9.022 billion CNY [1] Company Overview - JiuZhiTang Co., Ltd. is located in Beijing and Changsha, established on May 12, 1999, and listed on June 28, 2000. The company specializes in the research, production, and sales of traditional Chinese medicine, biological pharmaceuticals, and cardiovascular drugs [1] - The revenue composition of JiuZhiTang includes prescription drugs (50.27%), OTC products (46.11%), other products (2.50%), health products (0.92%), and additional categories (0.20%) [1] Fund Holdings - Yimin Fund has a significant holding in JiuZhiTang, with the Yimin Innovation Advantage Mixed Fund (560003) holding 515,400 shares, representing 1.15% of the fund's net value, making it the ninth-largest holding. The estimated floating profit for today is approximately 262,900 CNY [2] - The Yimin Innovation Advantage Mixed Fund was established on July 11, 2007, with a current size of 434 million CNY. Year-to-date returns are 16.78%, ranking 4903 out of 8147 in its category, while the one-year return is 12.51%, ranking 4719 out of 8056 [2] Fund Manager Performance - The fund managers of Yimin Innovation Advantage Mixed Fund are Zhang Ting and Ma Quanlin. Zhang has a tenure of 2 years and 47 days, with a total fund size of 490 million CNY, achieving a best return of 46.45% and a worst return of 7.38% during her tenure [3] - Ma Quanlin has a tenure of 3 years and 70 days, also managing a fund size of 490 million CNY, with a best return of 51.43% and a worst return of -27.43% during his tenure [3]